Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000046801 | SCV000245886 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
Mendelics | RCV000046801 | SCV000886218 | pathogenic | Cystic fibrosis | 2018-11-05 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781263 | SCV000919173 | pathogenic | not specified | 2017-09-11 | criteria provided, single submitter | clinical testing | Variant summary: The CFTR c.3160C>G (p.His1054Asp) variant located in the ABC transporter type , transmembrane domain involves the alteration of a conserved nucleotide and 5/5 in silico tools predict a damaging outcome for this variant. This variant is absent in 112668 control chromosomes. A functional study, Van Goor_2013, found the variant to have a severe defect in CFTR processing and to have a small but significant response to ivacaftor. Multiple publications have cited the variant in affected compound heterozygote individuals. In addition, a reputable database classifies the variant as "pathogenic." Therefore, the variant of interest has been classified as "pathogenic." |
CFTR- |
RCV000046801 | SCV001169282 | pathogenic | Cystic fibrosis | 2018-01-29 | criteria provided, single submitter | curation | |
Labcorp Genetics |
RCV000046801 | SCV001589629 | pathogenic | Cystic fibrosis | 2022-08-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces histidine, which is basic and polar, with aspartic acid, which is acidic and polar, at codon 1054 of the CFTR protein (p.His1054Asp). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with cystic fibrosis (PMID: 7505690, 16931591, 20538955, 23951356; Invitae). ClinVar contains an entry for this variant (Variation ID: 53667). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). Experimental studies have shown that this missense change affects CFTR function (PMID: 8662892, 23891399). |
Baylor Genetics | RCV004566876 | SCV005057449 | pathogenic | Bronchiectasis with or without elevated sweat chloride 1 | 2024-01-09 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001826659 | SCV002083605 | pathogenic | CFTR-related disorder | 2019-04-04 | no assertion criteria provided | clinical testing |